GlycoT Awarded Phase I SBIR Grant

March 20, 2018

GlycoT was awarded a Phase I SBIR grant (1R43GM128547-01, $292,383) from NIGMS to develop a 13C-labeled IgG-Fc glycopeptide library using our technology platform, which could be applied as standards for absolute quantification of antibody glycosylation from recombinant antibodies and clinical samples for quality control of biologics manufacturing, and/or for diagnosis and biomarker discovery.

Research and Development Collaborations
To request a quote for our products, customized service, investment opportunities, or if you have any general inquiry for our company click the start now button.
Learn More